Together, these data suggest that IL-1β blockade might be particularly effective in treating lung cancer in the presence of oncogenic driver mutations, potentially making canakinumab more effective when combined with EGFR TKIs rather than with chemotherapy or immunotherapy. This evidence concerns the gene IL1B and lung carcinoma.